Lund, Sweden

Hooi Ching Lim

This inventor holds 1 USPTO granted patent. Top assignee: Xintela Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hooi Ching Lim. Retrieved from https://idiyas.com/inventor/hooi-ching-lim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hooi Ching Lim and Regenerative Skin-Treatment Research.

Introduction

Hooi Ching Lim is an inventor associated with Lund, Sweden, and Xintela AB. Her listed patent concerns the use of mesenchymal stem cells to treat skin defects.

Latest Patents

Lim is associated with 1 patent, titled “Mesenchymal stem cells for use in the treatment of skin defects.” The invention describes compositions containing integrin α10-selected mesenchymal stem cells and culture conditions intended to support cell viability, paracrine activity, and regenerative function. The disclosed approach aims to promote wound healing, modulate inflammation, and support re-epithelialization, with dosing parameters and administration routes for acute and chronic skin defects.

Career Highlights

Lim’s listed work connects her to Xintela AB and research into regenerative therapies for damaged skin tissue. The patent describes a cell-based approach intended to improve healing outcomes.

Collaborations

The provided information lists Evy Lundgren Åkerlund and Folke Sjöberg as Lim’s coworkers.

Conclusion

Hooi Ching Lim’s listed patent reflects research into integrin α10-selected mesenchymal stem cells as a potential treatment for skin defects.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…